Lupin has selected a CEO to lead its fresh API CDMO business venture, while the UK’s off-patent group BGMA has appointed a new vice-chair. Meanwhile, ChemWerth has welcomed a familiar face as its new president and Coherus has elected a new board member with a focus on immuno-oncology.

Public Company Edition: Insmed grossed $650m, Structure raised $476m and Merus brought in $400.2m after positive clinical trial results. But while CARGO raised $110m in a private placement and Day One sold a priority review voucher for $108m, Ikena, Takeda and others cut jobs.

The drug maker anticipates a smooth regulatory path and has already begun to rapidly expand its sales force across most of the US.

Cargo Therapeutics has got an early boost from its abstract to be presented the European meeting, while Shattuck has suffered on safety doubts for its CD47 inhibitor.